Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Link on Nelarabine in Newly Diagnosed T-Cell Malignancies

July 10th 2018

Michael Link, MD, Lydia J. Lee Professor in Pediatric Cancer, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care in Pediatric Oncology, discusses the randomized trial testing nelarabine in patients with T-cell malignancies.

Dr. Trotman Discusses Zanubrutinib in Waldenstrom's Macroglobulinemia

June 29th 2018

Judith Trotman, MBChB, FRACP, FRCPA, clinical professor of medicine, Concord Clinical School, director of Clinical Research Unit, Haematology Department, Concord Hospital, discusses zanubrutinib in patients with Waldenstrom's Macroglobulinemia.

Dr. Chari on the Subgroup Analysis of MMY1001 in Multiple Myeloma

June 29th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the subgroup analysis of MMY1001 in multiple myeloma.

EMA Committee Recommends CPX-351 Approval for 2 AML Types

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of CPX-351, a fixed-combination of daunorubicin and cytarabine, for adult patients with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.

Dr. Kreitman on Results of Moxetumomab Pasudotox in Hairy Cell Leukemia

June 28th 2018

Robert J. Kreitman, MD, chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, discusses the findings of moxetumomab pasudotox as a treatment for patients with relapsed/refractory hairy cell leukemia.

FDA Grants Glasdegib Priority Review for Frontline AML

June 28th 2018

The FDA has granted a priority review to a new drug application for glasdegib for use in combination with chemotherapy for the frontline treatment of patients with acute myeloid leukemia.

Dr. Richardson Discusses the Results of the OPTIMISMM Trial in Myeloma

June 23rd 2018

Paul Richardson, MD, clinical program leader, director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the results of the OPTIMISMM trial in patients with multiple myeloma.

Ruxolitinib Reaches 55% Response Rate in Pivotal GVHD Trial

June 22nd 2018

Ruxolitinib combined with corticosteroids induced an overall response rate of 55% at day 28 in patients with steroid-refractory acute graft-versus-host disease, meeting the primary endpoint of the phase II REACH1 trial.

Blinatumomab Granted Full EU Approval for B-cell Precursor ALL

June 19th 2018

The European Commission has granted blinatumomab full marketing authorization for the treatment of adult patients with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia, according to Amgen, the developer of the anti-CD19 immunotherapy.

Dr. Sallman on APR-246 Plus Azacitidine in TP53-Mutant MDS and AML

June 17th 2018

David Sallman, MD, assistant member, Moffitt Cancer Center, discusses the combination of APR-246 and azacitidine as a treatment for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Quizartinib Extends Survival in FLT3-ITD+ Relapsed/Refractory AML

June 17th 2018

Quizartinib reduced the risk of death by 24% compared with salvage chemotherapy in patients with FLT3-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.

CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL

June 16th 2018

A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.

Dr. Cortes on the Results of Quizartinib in Relapsed/Refractory AML

June 16th 2018

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the results of quizartinib in patients with relapsed/refractory acute myeloid leukemia.

Compound CAR T-Cell Therapy Shows Promise for AML

June 16th 2018

A compound CLL1/CD33-targeted CAR T-cell therapy showed a complete remission with minimal residual disease (MRD) negativity in a single-patient case study from an ongoing phase I study for relapsed/refractory acute myeloid leukemia.

Dr. Garcia-Sanz on Brentuximab Vedotin Plus ESHAP in Hodgkin Lymphoma

June 15th 2018

Ramon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses the results of brentuximab vedotin (Adcetris) plus ESHAP followed by autologous stem cell transplant in patients with relapsed/refractory Hodgkin lymphoma.

Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ Lymphomas

June 15th 2018

Susan E. Prockop, MD, pediatric oncologist, Memorial Sloan Kettering Cancer Center, discusses tabelecleucel in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphomas.

PET-Guided De-escalation Effective in Advanced Hodgkin Lymphoma

June 15th 2018

PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.

FDA Approves Pembrolizumab for Relapsed/Refractory PMBCL

June 13th 2018

The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or those who have relapsed after 2 or more prior lines of therapy.

FDA Adds Survival Data to Carfilzomib Myeloma Label

June 12th 2018

The FDA approved a supplemental new drug application adding overall survival data from the phase III ASPIRE trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.

Boom in Targeted Agents Propels AML Treatment Into a New Era of Personalized Care

June 12th 2018

During an OncLive Peer Exchange® a panel of AML experts discussed these newly approved agents and provided insight on how they are rapidly changing the standard of care for various AML subgroups.